Tango for Neuropathy
(DAANCE Trial)
Trial Summary
What is the purpose of this trial?
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Research Team
Lise B Worthen-Chaudhari, PhD, MFA, CMES
Principal Investigator
Ohio State University
Maryam B Lustberg, MD, MPH
Principal Investigator
Yale University
Eligibility Criteria
This trial is for breast cancer survivors who finished taxane-based chemotherapy at least 3 months ago, are experiencing neuropathy symptoms, and have a risk of falling. They must be able to follow study instructions. People with vestibular dysfunction, severe diabetes, hearing loss, or unstable medical conditions that prevent physical activity cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Control
Participants receive 4 weeks of usual care followed by optional 1-way crossover to 8 weeks of partnered, adapted tango dance
Experimental
Participants receive 8 weeks of partnered, adapted tango dance
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Adapted Argentine Tango
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
Emory University
Collaborator
National Institute on Aging (NIA)
Collaborator
Yale University
Collaborator